Scientists working on longevity research are moving forward with human testing of experimental treatments designed to reverse age-related cellular damage. Harvard Medical School professor David Sinclair plans to conduct human trials of an oral "reprogramming" drug as part of a $101 million competition, according to reports. Sinclair has previously stated that such treatments could potentially make patients 10 years younger biologically.

Separately, a longevity startup has begun dosing the first human subject with ER-100, a technology the company claims can reverse aging in cells. This marks the initial human testing of the experimental treatment, which is being evaluated for its potential to reverse age-related sight loss.

Meanwhile, researchers have documented a case report of a woman with advanced Alzheimer's disease who reportedly showed significant improvements in brain function and regained speech and memories after taking psilocybin mushrooms. The case study suggests potential therapeutic applications for psychedelic compounds in treating neurodegenerative conditions.

These developments represent different approaches to addressing age-related decline, from cellular reprogramming technologies to psychedelic-assisted therapies. The research efforts are part of a broader scientific push to understand and potentially reverse the biological processes associated with aging and age-related diseases.

The field of longevity research has gained increased attention and funding in recent years, with both academic institutions and private companies investing in experimental approaches to extend healthy human lifespan.